Ensign Peak Advisors Inc boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 7.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 586,128 shares of the company's stock after acquiring an additional 39,293 shares during the period. Ensign Peak Advisors Inc owned 0.47% of Vaxcyte worth $47,980,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in Vaxcyte by 53.7% in the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after purchasing an additional 25,257 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vaxcyte by 23.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after buying an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of Vaxcyte by 53.7% during the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock valued at $33,860,000 after buying an additional 144,516 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after acquiring an additional 246,049 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.
Insider Transactions at Vaxcyte
In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.10% of the company's stock.
Analyst Ratings Changes
A number of analysts have commented on PCVX shares. Needham & Company LLC reissued a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Bank of America lowered their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim restated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Finally, The Goldman Sachs Group decreased their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Vaxcyte presently has a consensus rating of "Buy" and a consensus price target of $136.50.
Read Our Latest Research Report on Vaxcyte
Vaxcyte Stock Performance
Vaxcyte stock traded down $1.54 during midday trading on Tuesday, reaching $30.05. 2,665,021 shares of the stock were exchanged, compared to its average volume of 1,321,417. The firm has a market cap of $3.88 billion, a PE ratio of -6.53 and a beta of 1.27. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The company's fifty day moving average is $45.81 and its 200-day moving average is $73.63.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the company posted ($0.85) EPS. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
